These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38464052)

  • 1. Design of the STRIVE-IPF Trial- Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.
    Kulkarni T; Criner GJ; Kass DJ; Rosas IO; Scholand MB; Dilling DF; Summer R; Duncan SR
    Res Sq; 2024 Feb; ():. PubMed ID: 38464052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis.
    Kulkarni T; Criner GJ; Kass DJ; Rosas IO; Scholand MB; Dilling DF; Summer R; Duncan SR
    BMC Pulm Med; 2024 Mar; 24(1):143. PubMed ID: 38509495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.
    Donahoe M; Valentine VG; Chien N; Gibson KF; Raval JS; Saul M; Xue J; Zhang Y; Duncan SR
    PLoS One; 2015; 10(6):e0127771. PubMed ID: 26083430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations.
    Kulkarni T; Valentine VG; Fei F; Tran-Nguyen TK; Quesada-Arias LD; Mkorombindo T; Pham HP; Simmons SC; Dsouza KG; Luckhardt T; Duncan SR
    PLoS One; 2021; 16(11):e0260345. PubMed ID: 34813613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial.
    Li JS; Zhang HL; Guo W; Wang L; Zhang D; Zhao LM; Zhou M
    J Integr Med; 2023 Nov; 21(6):543-549. PubMed ID: 37993378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of traditional Chinese medicine in patients with acute exacerbation of idiopathic pulmonary fibrosis: study protocol for randomized, controlled, exploratory clinical trial.
    Hailong Z; Jiansheng L; Wen G; Lu W; Dong Z; Limin Z; Miao Z; Weixian L
    Trials; 2022 Feb; 23(1):103. PubMed ID: 35109889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial.
    Anstrom KJ; Noth I; Flaherty KR; Edwards RH; Albright J; Baucom A; Brooks M; Clark AB; Clausen ES; Durheim MT; Kim DY; Kirchner J; Oldham JM; Snyder LD; Wilson AM; Wisniewski SR; Yow E; Martinez FJ;
    Respir Res; 2020 Mar; 21(1):68. PubMed ID: 32164673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema.
    Zantah M; Dotan Y; Dass C; Zhao H; Marchetti N; Criner GJ
    Respir Res; 2020 Jun; 21(1):164. PubMed ID: 32605574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
    BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies.
    Biondini D; Balestro E; Sverzellati N; Cocconcelli E; Bernardinello N; Ryerson CJ; Spagnolo P
    Expert Rev Respir Med; 2020 Apr; 14(4):405-414. PubMed ID: 31994940
    [No Abstract]   [Full Text] [Related]  

  • 12. Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.
    Okuda R; Hagiwara E; Katano T; Ikeda S; Sekine A; Kitamura H; Baba T; Okudela K; Ohashi K; Ogura T
    Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(1):39-46. PubMed ID: 32476935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
    Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
    Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial.
    Hayakawa S; Matsuzawa Y; Irie T; Rikitake H; Okada N; Suzuki Y
    Multidiscip Respir Med; 2016; 11():38. PubMed ID: 27826444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis: a proof of concept study.
    Tsushima K; Yamaguchi K; Kono Y; Yokoyama T; Kubo K; Matsumura T; Ichimura Y; Abe M; Terada J; Tatsumi K
    Pulm Pharmacol Ther; 2014 Dec; 29(2):233-40. PubMed ID: 24836398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review.
    Luppi F; Cerri S; Taddei S; Ferrara G; Cottin V
    Intern Emerg Med; 2015 Jun; 10(4):401-11. PubMed ID: 25672832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat.
    Kulkarni T; Duncan SR
    Curr Pulmonol Rep; 2019 Dec; 8(4):123-130. PubMed ID: 33312849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.